Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Income Strategy: 2 Terrific Blue Chips Yielding 5-7%
08:00am, Saturday, 15'th Mar 2025
Market volatility favors income investors with dry powder on hand to buy undervalued dividend stocks. Pfizer offers a 6.7% yield, trading at a low valuation with resilient drug portfolio growth and co
Calls of the Day: Invitation Homes, Pfizer and Roblox
01:34pm, Thursday, 13'th Mar 2025
The Investment Committee debate the latest Calls of the Day.
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies sh
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
12:30pm, Tuesday, 11'th Mar 2025
Arvinas, Inc. ARVN and Pfizer Inc. PFE released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic
Pfizer: Undervalued Safe Haven In Risk-Off Market
09:30am, Tuesday, 11'th Mar 2025
Pfizer remained flat while the S&P 500 dropped 2.25%, reinforcing its defensive strength in a risk-off market. CY24 revenue reached $63.6B (+6.7% YoY), with non-COVID sales growing 12%, exceeding expe
Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study
06:58am, Tuesday, 11'th Mar 2025
Pfizer and Arvinas' experimental drug to treat a type of breast cancer met the main goal in a late-stage study, the companies said on Tuesday.
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
06:45am, Tuesday, 11'th Mar 2025
– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival –
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
10:06am, Monday, 10'th Mar 2025
BioNTech SE BNTX on Monday reported fourth-quarter per-share earnings of 1.08 euros ($1.17), down from 1.88 euros reported a year ago compared to the consensus of 38 cents.
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?
09:55am, Monday, 10'th Mar 2025
Investors may stay invested in PFE stock to see how its new growth drivers perform.
3 Monster Dividend Stocks Paying Over 5%
11:31am, Sunday, 09'th Mar 2025
Passive income investors looking to get paid to navigate a more turbulent stock market should look to the many dividend stocks while their yields are still north of 5%.
3 Top Dividend Stocks to Buy in March
08:30am, Saturday, 08'th Mar 2025
Investing in dividend stocks can be a great strategy, especially if you pick solid companies that pay reliable and high-yield dividends. While dividend stocks don't always offer the same excitement as
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Friday, 07'th Mar 2025
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
09:34am, Friday, 07'th Mar 2025
Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article
The Nasdaq Is Falling: 4 of the Safest Stocks to Buy Right Now
04:06am, Friday, 07'th Mar 2025
For the better part of the last 2.5 years, the bulls have been calling the shots on Wall Street. The ageless Dow Jones Industrial Average, benchmark S&P 500, and growth-dominated Nasdaq Composite (^IX
The Smartest Dividend Stocks to Buy With $2,000 Right Now
03:15am, Friday, 07'th Mar 2025
Need investment income? Dividend stocks are obviously your best bet.
